The renewed strength in TAVR, following a slowdown last year tied to heart team capacity challenges at hospitals, prompted ...

Edwards TAVR segment reached $1.1bn in Q2 2025, up 8.9% compared to Q2 2024, while its heart valve segment increased by 61.9% ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy TAVR system.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights. Q2 sales g ...

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

Edwards Lifesciences stock surged late Thursday after the medtech hiked its outlook following a key setback for rival Boston ...

Edwards Lifesciences reported Street-beating Q2 results, upping the lower end of its full-year sales guidance.

Edwards Lifesciences Corp (EW) reports a 10.6% sales increase and raises full-year guidance, driven by robust performance in ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Background Current risk scores inadequately predict long-term mortality after transcatheter aortic valve replacement (TAVR), ...

Heart Valve Replaced Without Surgery Through Arm Artery - First Ever Percutaneous Trans-Axillary TAVI in India ...